These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 21988449)

  • 21. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.
    Cuthbertson DJ; Irwin A; Gardner CJ; Daousi C; Purewal T; Furlong N; Goenka N; Thomas EL; Adams VL; Pushpakom SP; Pirmohamed M; Kemp GJ
    PLoS One; 2012; 7(12):e50117. PubMed ID: 23236362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.
    González C; Beruto V; Keller G; Santoro S; Di Girolamo G
    Expert Opin Investig Drugs; 2006 Aug; 15(8):887-95. PubMed ID: 16859392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The novel use of GLP-1 analogue and insulin combination in type 2 diabetes mellitus.
    Baruah MP; Kalra S
    Recent Pat Endocr Metab Immune Drug Discov; 2012 May; 6(2):129-35. PubMed ID: 22435393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
    Miller LA; Burudpakdee C; Zagar A; Bhosle M; Reaney M; Schabert VF; Bruhn D
    J Med Econ; 2012; 15(4):746-57. PubMed ID: 22443463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes.
    Ross SA
    Curr Med Res Opin; 2015 Jan; 31(1):125-35. PubMed ID: 25299351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing outcomes for GLP-1 agonists.
    Freeman JS
    J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS15-20. PubMed ID: 21389295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.
    Alves C; Batel-Marques F; Macedo AF
    Diabetes Res Clin Pract; 2012 Nov; 98(2):271-84. PubMed ID: 23010561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liraglutide in oral antidiabetic drug combination therapy.
    Garber AJ
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Basal insulin or longacting GLP-1 receptor agonists-making the right choice.
    Bloomgarden ZT
    Lancet Diabetes Endocrinol; 2014 Jun; 2(6):439-41. PubMed ID: 24731676
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparing diabetes drugs--helping clinical decisions?
    Thethi T; Fonseca V
    Lancet; 2013 Jan; 381(9861):93-4. PubMed ID: 23141811
    [No Abstract]   [Full Text] [Related]  

  • 31. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects.
    Mundil D; Cameron-Vendrig A; Husain M
    Diab Vasc Dis Res; 2012 Apr; 9(2):95-108. PubMed ID: 22496442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of type 2 diabetes mellitus with GLP-1 agonists].
    Haluzík M; Urbanová M; Trachta P
    Vnitr Lek; 2011 Apr; 57(4):411-5. PubMed ID: 21612070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liraglutide for type 2 diabetes?
    Drug Ther Bull; 2010 May; 48(5):50-3. PubMed ID: 20447980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New therapies for diabetes.
    Green DE
    Clin Cornerstone; 2007; 8(2):58-63; discussion 64-5. PubMed ID: 18357956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].
    Consoli A; Di Biagio R
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):5-9. PubMed ID: 22158421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GLP-1 receptor agonists: effects on cardiovascular risk reduction.
    Lorber D
    Cardiovasc Ther; 2013 Aug; 31(4):238-49. PubMed ID: 23865382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide.
    Voukali M; Kastrinelli I; Stragalinou S; Tasiopoulou D; Paraskevopoulou P; Katsilambros N; Kokkinos A; Tentolouris N; Ioannidis I
    J Diabetes Res; 2014; 2014():304032. PubMed ID: 25165723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of exenatide and liraglutide in Denmark: a drug utilization study.
    Pottegård A; Bjerregaard BK; Larsen MD; Larsen KS; Hallas J; Knop FK; Moreno SI
    Eur J Clin Pharmacol; 2014 Feb; 70(2):205-14. PubMed ID: 24145815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peptide complex containing GLP-1 exhibited long-acting properties in the treatment of type 2 diabetes.
    Zheng X; Li Y; Li X; Tang L; Xu W; Gong M
    Diabetes Res Clin Pract; 2011 Sep; 93(3):410-20. PubMed ID: 21641071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus.
    Hoogwerf BJ
    Cleve Clin J Med; 2006 May; 73(5):477-84. PubMed ID: 16708716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.